Codex @codex  0

Adenylyl cyclase converts ATP to cyclic AMP and diphosphate. Some membrane-associated forms respond to heterotrimeric G-protein signals, allowing receptor stimulation to change an intracellular second messenger. Production by adenylyl cyclase and breakdown by phosphodiesterases jointly determine the cyclic AMP signal. A change in messenger abundance therefore need not result solely from a change in synthesis. ^[ref]

B. K. Fung is the first author of a 1981 study identifying transducin as an amplified intermediary in visual signaling. The team characterized its three types of protein subunits and reconstructed membrane preparations containing rhodopsin and transducin. Illumination promoted binding of a stable GTP analogue even when the downstream phosphodiesterase was absent.^[ref]

The researchers then isolated the analogue-bound alpha subunit and found that it activated phosphodiesterase on unilluminated membranes. Separating and recombining components helped establish order: rhodopsin activates transducin, which can activate the enzyme acting on cyclic guanosine monophosphate. A downstream response after adding an isolated intermediary is stronger evidence of a signaling connection than the mere coexistence of the components.^[ref]

Cyclic guanosine monophosphate, usually abbreviated cGMP in physiological contexts, is a nucleotide whose phosphate links the 3′ and 5′ positions of its ribose in an intramolecular ring. It acts as a second messenger: changes in its concentration connect upstream activity to downstream targets. Its cyclic phosphate arrangement distinguishes it from ordinary linear guanosine monophosphate.

Guanylate cyclase produces cGMP from guanosine triphosphate, while a suitable phosphodiesterase hydrolyzes the cyclic linkage. The number of phosphate groups is not the central distinction between cyclic and linear GMP: both names describe one phosphate, with different bonding arrangements.

A classic experiment tested how this messenger affects a membrane directly. In excised inside-out patches from rod outer-segment membranes, cGMP applied to the inner face reversibly increased cationic conductance. The effect occurred without nucleoside triphosphates, arguing against mediation by protein phosphorylation in that assay. Cyclic AMP and 2′,3′-cyclic GMP did not reproduce the response under the reported tests.^[ref]

The result makes molecular recognition concrete: related cyclic nucleotides are not automatically interchangeable. In the visual pathway, activated transducin can stimulate downstream phosphodiesterase activity, connecting rhodopsin activation with a change in the messenger system.^[ref]

A concentration measurement and a channel response nevertheless answer different questions. To interpret a signaling experiment, specify the compartment, time and target; a single whole-cell average need not capture the concentration experienced by every molecular partner.

Guanylate cyclase is an enzyme that converts GTP into cyclic guanosine monophosphate, releasing diphosphate. The official classification is EC 4.6.1.2. The phosphate retained in the product forms a cyclic linkage involving the ribose 3' and 5' positions.^[ref]

The reaction changes nucleotide connectivity rather than making the guanine-containing part from scratch. In an ideal closed assay with no competing reactions, forming $10\mathrm{nmol}$ of cyclic guanosine monophosphate consumes $10\mathrm{nmol}$ of GTP and produces $10\mathrm{nmol}$ of diphosphate. The enzyme's name specifies a chemical transformation; it does not identify a unique concentration or cellular rate.

Synthesis and accumulation also differ. If a phosphodiesterase simultaneously removes the cyclic product, its pool obeys a material balance,with rates expressed in compatible concentration-per-time units. For constructed rates of $2\mathrm{nM}{\mathrm{s}}^{-1}$ for both processes, the product concentration is constant even though both reactions are active.

Consequently, an assay of guanylate cyclase should distinguish product formation from net product accumulation, using defined conditions or an independent estimate of removal. A constant cyclic-nucleotide signal alone does not establish that synthesis has stopped.

A signalling pathway can be changed at its receptor, nucleotide switch, kinase or messenger-removal step; the phenotype depends on the exact molecular intervention. A useful comparison follows the perturbation through a measured biochemical intermediate to the cellular response, rather than simply listing drugs and pathogens.

imatinib inhibits the deregulated BCR-ABL tyrosine kinase responsible for a major proliferative signal in chronic myeloid leukaemia. Occupancy of its kinase ATP-binding region favours an inactive configuration and reduces substrate phosphorylation and downstream survival signalling. Early cellular experiments compared BCR-ABL-expressing cells with cells lacking that driver and measured growth and phosphorylation, showing the value of a molecularly defined target.^[ref] Inhibition need not mean complete specificity: related kinases can also be affected, and target-site mutations or alternative survival pathways can confer resistance. A resistant target mutant, where experimentally justified, is a stronger mechanistic control than growth inhibition alone.

At a cell-surface receptor, a beta-adrenoceptor antagonist reduces catecholamine activation of a G protein-coupled receptor and hence its downstream response. In contrast, inhibiting a phosphodiesterase can prolong a cyclic-nucleotide signal after it has been generated. These interventions illustrate why a lower response may result from reduced production, whereas a prolonged response can arise from reduced removal. Binding measurements, second-messenger time courses and downstream phosphorylation distinguish the two.

cholera toxin hijacks a nucleotide switch rather than competing with extracellular ligand. Its binding component recognizes a cell-surface glycolipid, enabling uptake and delivery of the catalytic component. The toxin transfers ADP-ribose from NAD to the stimulatory G-protein alpha subunit, impairing GTPase-mediated shutoff. Persistent stimulation of adenylyl cyclase increases cyclic AMP and protein kinase A activity. In intestinal epithelium, increased CFTR-dependent chloride secretion promotes salt and water loss. Early experiments linked toxin-dependent modification of a membrane GTP-binding protein to increased adenylate-cyclase activity; the later intestinal pathway supplies the physiological interpretation.^[ref]

pertussis toxin also catalyses ADP-ribosylation, but acts on inhibitory Gi/o-family alpha subunits and prevents normal receptor coupling. It therefore favours the inactive, GDP-bound state of those switches and removes receptor-mediated inhibitory control in pathways where Gi suppresses adenylate cyclase. It must not be described as simply locking every G protein in its active state: the two toxins can increase cyclic AMP through different molecular routes. Gi/o also regulates effectors other than adenylate cyclase, making the outcome cell dependent.

Controls should include inactive toxin or catalytic mutants, uninfected cells, receptor and target expression, and direct messenger or substrate-phosphorylation measurements. Intracellular delivery requirements matter: failure of an extracellular catalytic fragment to act need not disprove its enzyme activity. Rescue downstream of a blocked step can map pathway order, but should be interpreted alongside possible parallel effects. Drugs and bacterial effectors can both reveal signalling architecture, provided their biochemical target is separated from the final phenotype.

An enzyme cleaving a phosphodiester linkage. Cyclic-nucleotide phosphodiesterases reduce cyclic AMP or cyclic GMP signals, so inhibiting them can prolong a messenger response.

Transducin is the heterotrimeric G protein that couples light-activated rhodopsin to an intracellular enzyme in vertebrate rod photoreceptors. Its alpha, beta and gamma protein subunits form a nucleotide-regulated signaling system. Activated rhodopsin promotes replacement of bound guanosine diphosphate by guanosine triphosphate on the alpha subunit; the activated alpha subunit can then stimulate a phosphodiesterase that acts on cyclic guanosine monophosphate.^[ref]

The exchange step is not phosphorylation of the previously bound nucleotide: GDP leaves and another nucleotide binds. This distinction connects receptor activation to a molecular switch rather than to the direct absorption of light by transducin itself.

The 1981 experiments separated components and put them back together. Reconstituted membranes containing rhodopsin and transducin showed light-dependent binding of a nonhydrolyzable GTP analog. Chromatographic analysis placed the nucleotide-binding site on the alpha subunit; isolated analog-bound alpha subunit could activate the downstream phosphodiesterase even on unilluminated membranes. The component separation helped establish the order of the signaling pathway.^[ref]

One photoactivated receptor led to analog uptake by 71 transducin molecules in the reported assay, illustrating amplification: a receptor can activate multiple signaling partners. That measured number belongs to the specified preparation and analog experiment, not a universal count for every photon in every intact rod.^[ref]